Business Context and Reporting Period
This Form 6-K filing by Ascendis Pharma A/S covers the month of April 2026. The report serves primarily to update the International Securities Identification Number (ISIN) for the Company's ordinary shares following their direct listing on The Nasdaq Global Select Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is an administrative update regarding securities identification and does not contain financial statements or performance metrics.
Material Changes
- ISIN Update: The ISIN for the Company's ordinary shares has changed from DK0060606333 to DK0060615755, as confirmed by the National Numbering Agency for Denmark.
- Unchanged Identifiers: The CUSIP number (K08588103) and the ticker symbol (ASND) remain unchanged.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document focuses solely on the correction of the ISIN and incorporation by reference into existing registration statements.
Investor Verification Checklist
- Verify the new ISIN (DK0060615755) in trading systems and brokerage accounts.
- Confirm that the CUSIP (K08588103) and ticker (ASND) remain active and unchanged.
- Review the referenced Form S-8 and Form F-3 registration statements for any superseding information regarding the share listing.